Solasia Pharma K.K
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial d… Read more
Market Cap & Net Worth: Solasia Pharma K.K (9SO)
Solasia Pharma K.K (F:9SO) has a market capitalization of $39.37 Million (€38.35 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22978 globally and #2506 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Solasia Pharma K.K's stock price €0.15 by its total outstanding shares 255699867 (255.70 Million).
Solasia Pharma K.K Market Cap History: 2017 to 2026
Solasia Pharma K.K's market capitalization history from 2017 to 2026. Data shows change from $754.86 Million to $39.37 Million (-26.97% CAGR).
Solasia Pharma K.K Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Solasia Pharma K.K's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.16x
Solasia Pharma K.K's market cap is 0.16 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $754.86 Million | $410.85 Million | -$1.01 Billion | 1.84x | N/A |
| 2018 | $296.59 Million | $318.00 Million | -$2.42 Billion | 0.93x | N/A |
| 2019 | $391.08 Million | $1.31 Billion | -$1.87 Billion | 0.30x | N/A |
| 2020 | $236.22 Million | $454.00 Million | -$4.13 Billion | 0.52x | N/A |
| 2021 | $211.29 Million | $559.00 Million | -$2.48 Billion | 0.38x | N/A |
| 2022 | $88.71 Million | $1.09 Billion | -$2.55 Billion | 0.08x | N/A |
| 2023 | $70.34 Million | $617.00 Million | -$1.11 Billion | 0.11x | N/A |
| 2024 | $50.66 Million | $316.00 Million | -$1.94 Billion | 0.16x | N/A |
Competitor Companies of 9SO by Market Capitalization
Companies near Solasia Pharma K.K in the global market cap rankings as of March 19, 2026.
Key companies related to Solasia Pharma K.K by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Solasia Pharma K.K Historical Marketcap From 2017 to 2026
Between 2017 and today, Solasia Pharma K.K's market cap moved from $754.86 Million to $ 39.37 Million, with a yearly change of -26.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €39.37 Million | +12.78% |
| 2025 | €34.91 Million | -31.09% |
| 2024 | €50.66 Million | -27.99% |
| 2023 | €70.34 Million | -20.71% |
| 2022 | €88.71 Million | -58.01% |
| 2021 | €211.29 Million | -10.56% |
| 2020 | €236.22 Million | -39.60% |
| 2019 | €391.08 Million | +31.86% |
| 2018 | €296.59 Million | -60.71% |
| 2017 | €754.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Solasia Pharma K.K was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $39.37 Million USD |
| MoneyControl | $39.37 Million USD |
| MarketWatch | $39.37 Million USD |
| marketcap.company | $39.37 Million USD |
| Reuters | $39.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.